Regeneron, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from Canaccord Genuity maintained a Buy rating on the stock and has a $850.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
John Newman’s rating is based on several positive developments for Regeneron. The recent FDA approval of EYLEA HD for macular edema following retinal vein occlusion, along with the approval for 4-week dosing intervals, marks a significant milestone. This approval comes at a crucial time, especially after the challenges faced due to issues at the Catalent facility, and is expected to sustain EYLEA HD’s sales momentum into 2026.
Furthermore, Regeneron’s strategic investments in new manufacturing sites and the anticipated approval of the pre-filled syringe in May 2026 position the company for future growth. The continued strong performance of Dupixent and promising data from the Factor XI program also contribute to a positive outlook. These factors, combined with potential pipeline successes and revenue growth, support the Buy rating and the $850 price target for Regeneron’s stock.
In another report released yesterday, Bernstein also assigned a Buy rating to the stock with a $818.00 price target.
REGN’s price has also changed moderately for the past six months – from $596.540 to $702.750, which is a 17.80% increase.